Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.66 |
| ▸ | RAB9A | P51151 | 5/20 | 0.66 |
| ▸ | LMNA | P02545 | 4/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 4/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | HTR1B | P28222 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9051173 | 0.98 | MAPT (0.64) | MAPTRAB9ALMNASMN1; SMN2NPC1 | |
| Hydrochloric Acid SCHEMBL5838247 | 0.98 | MAPT (0.64) | MAPTRAB9ALMNASMN1; SMN2NPC1 | |
| SCHEMBL16854230 | 0.91 | RAB9A (0.65) | MAPTRAB9ALMNASMN1; SMN2NPC1 | |
| SCHEMBL15533104 | 0.90 | MAPT (0.69) | MAPTRAB9ALMNASMN1; SMN2NPC1 | |
| SCHEMBL10879313 | 0.85 | RAB9A (0.60) | MAPTRAB9ALMNASMN1; SMN2NPC1 | |
| SCHEMBL29357142 | 0.84 | KDM4E (0.79) | MAPTRAB9ALMNASMN1; SMN2NPC1 | |
| SCHEMBL6031547 | 0.84 | KDM4E (0.79) | MAPTRAB9ALMNASMN1; SMN2NPC1 | |
| SCHEMBL3268052 | 0.82 | RAB9A (0.66) | MAPTRAB9ALMNASMN1; SMN2NPC1 | |
| SCHEMBL9302662 | 0.82 | RAB9A (0.66) | MAPTRAB9ALMNASMN1; SMN2NPC1 | |
| SCHEMBL2485504 | 0.82 | MAPT (0.66) | MAPTRAB9ALMNASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2039685-B1 | Heterobicyclic compounds as P38 inhibitors | ARRAY BIOPHARMA INC (US) | 2012-12-26 | — | — | EP | claimed |
| EP-0445731-B1 | Azabicyclo and azacyclo oxime and amine cholinergic agents and pharmaceutically acceptable salts thereof | WARNER LAMBERT CO (US) | 1996-01-10 | — | — | EP | claimed |
| US-5482938-A | Azabicyclo and azacyclo oxime and amine cholinergic agents and methods of treatment | WARNER-LAMBERT COMPANY (US) | 1996-01-09 | — | — | US | claimed |
| US-4192893-A | BASED ON SEROTONINE PROTENTIATION | U.S. PHILIPS CORPORATION (US) | 1980-03-11 | — | — | US | claimed |
| CN-109563073-B | For the treatment of para-5-HT1AReceptor-controlled serotonergic disease-modulating compounds | 诺罗利西斯公司 | 2021-12-07 | — | — | CN | disclosed |
| EP-3475268-B9 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | NEUROLIXIS (FR) | 2021-04-21 | — | — | EP | disclosed |
| WO-2021029434-A1 | THERAPEUTIC AGENT FOR DROPPED HEAD SYNDROME AND THORACOLUMBAR DEFORMITY | 石井 賢 | 2021-02-18 | — | — | WO | disclosed |
| EP-3475268-B1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | NEUROLIXIS (FR) | 2020-08-19 | — | — | EP | disclosed |
| US-10562853-B2 | Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors | NEUROLIXIS (FR) | 2020-02-18 | — | — | US | disclosed |
| CN-110742071-A | Application of fluvoxamine maleate in preparation of bactericide for preventing and treating plant diseases caused by plant pathogenic bacteria | 青岛农业大学 | 2020-02-04 | — | — | CN | disclosed |
| US-20190194132-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | NEUROLIXIS (FR) | 2019-06-27 | — | — | US | disclosed |
| EP-3475268-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | Neurolixis (FR) | 2019-05-01 | — | — | EP | disclosed |
| US-5554383-A | ADMINISTERING SELECTIVE SEROTONIN REUPTAKE INHIBITOR | TRUSTEES OF TUFTS COLLEGE (US) | 1996-09-10 | — | — | US | disclosed |
| EP-0709378-A2 | Aminoalkyloximes, a process for their preparation, their use as medicaments and intermediate compounds | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1996-05-01 | — | — | EP | disclosed |
| EP-0659082-A1 | USE OF CYTOCHROME P450 INHIBITORS FOR INHIBITING THE METABOLISM OF NITROGEN SUBSTITUTED ACRIDINE | WARNER-LAMBERT COMPANY (US) | 1995-06-28 | — | — | EP | disclosed |
| US-5319140-A | Antibiotics | HOFFMANN-LA ROCHE INC. (US) | 1994-06-07 | — | — | US | disclosed |
| WO-1994005296-A2 | USE OF CYTOCHROME P450 INHIBITORS FOR INHIBITING THE METABOLISM OF NITROGEN SUBSTITUTED ACRIDINE | WARNER-LAMBERT COMPANY (US) | 1994-03-17 | — | — | WO | disclosed |
| US-5138066-A | Intermediates for cephalosporins with sulfur-containing oxyimino side chain | HOFFMANN-LA ROCHE, INC. (US) | 1992-08-11 | — | — | US | disclosed |
| US-5073550-A | Bactericides | HOFFMANN-LA ROCHE INC. (US) | 1991-12-17 | — | — | US | disclosed |
| US-5036064-A | Antibiotics | HOFFMANN-LA ROCHE INC. (US) | 1991-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562853-B2 | Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors | HTR5A, HTR1A, HTR1E | MAPT 3661/4885RAB9A 2484/4885LMNA 4173/4885 |
| US-20190194132-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | HTR5A, HTR1A, HTR1E | MAPT 3661/4885RAB9A 2484/4885LMNA 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.